ObsEva (OBSV) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrends OBSV vs. CEMI, ACST, MRKR, LIAN, KALA, LGVN, DYAI, ELEV, ALGS, and ALTSShould you be buying ObsEva stock or one of its competitors? The main competitors of ObsEva include Chembio Diagnostics (CEMI), Acasti Pharma (ACST), Marker Therapeutics (MRKR), LianBio (LIAN), KALA BIO (KALA), Longeveron (LGVN), Dyadic International (DYAI), Elevation Oncology (ELEV), Aligos Therapeutics (ALGS), and Janone (ALTS). ObsEva vs. Chembio Diagnostics Acasti Pharma Marker Therapeutics LianBio KALA BIO Longeveron Dyadic International Elevation Oncology Aligos Therapeutics Janone Chembio Diagnostics (NASDAQ:CEMI) and ObsEva (NASDAQ:OBSV) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations. Is CEMI or OBSV more profitable? ObsEva has a net margin of 0.00% compared to Chembio Diagnostics' net margin of -47.03%. Chembio Diagnostics' return on equity of -113.57% beat ObsEva's return on equity.Company Net Margins Return on Equity Return on Assets Chembio Diagnostics-47.03% -113.57% -38.22% ObsEva N/A -416.36%-92.01% Does the media favor CEMI or OBSV? In the previous week, ObsEva had 1 more articles in the media than Chembio Diagnostics. MarketBeat recorded 1 mentions for ObsEva and 0 mentions for Chembio Diagnostics. Chembio Diagnostics' average media sentiment score of 0.00 equaled ObsEva'saverage media sentiment score. Company Overall Sentiment Chembio Diagnostics Neutral ObsEva Neutral Do analysts rate CEMI or OBSV? Given ObsEva's higher possible upside, analysts plainly believe ObsEva is more favorable than Chembio Diagnostics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chembio Diagnostics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/AObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Does the MarketBeat Community favor CEMI or OBSV? ObsEva received 46 more outperform votes than Chembio Diagnostics when rated by MarketBeat users. Likewise, 51.62% of users gave ObsEva an outperform vote while only 51.22% of users gave Chembio Diagnostics an outperform vote. CompanyUnderperformOutperformChembio DiagnosticsOutperform Votes27351.22% Underperform Votes26048.78% ObsEvaOutperform Votes31951.62% Underperform Votes29948.38% Do institutionals & insiders hold more shares of CEMI or OBSV? 8.6% of Chembio Diagnostics shares are held by institutional investors. Comparatively, 17.5% of ObsEva shares are held by institutional investors. 3.3% of Chembio Diagnostics shares are held by insiders. Comparatively, 14.4% of ObsEva shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has higher valuation & earnings, CEMI or OBSV? Chembio Diagnostics has higher revenue and earnings than ObsEva. Chembio Diagnostics is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChembio Diagnostics$48.34M0.35-$23.29M-$1.20-0.38ObsEva$20.11M0.00-$58.38M-$0.92N/A Which has more volatility & risk, CEMI or OBSV? Chembio Diagnostics has a beta of 1.85, suggesting that its share price is 85% more volatile than the S&P 500. Comparatively, ObsEva has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. SummaryObsEva beats Chembio Diagnostics on 9 of the 14 factors compared between the two stocks. Ad Porter & CompanyThe Final FrontierAnd a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt to discredit it, tar and feather it, and convince you not to watch it. That’s because it tells the shocking truth about the current AI mania… and why investors in big tech companies like Nvidia, Meta, Alphabet, and Microsoft could be in for a whole world of pain.Here’s the full story for you. Get ObsEva News Delivered to You Automatically Sign up to receive the latest news and ratings for OBSV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OBSV vs. The Competition Export to ExcelMetricObsEvaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.94M$6.75B$5.04B$8.43BDividend YieldN/A7.94%7.52%4.16%P/E Ratio-0.1112.17130.2316.67Price / SalesN/A270.431,720.2276.26Price / CashN/A46.0936.9133.54Price / BookN/A5.284.604.98Net Income-$58.38M$151.33M$114.94M$224.26M ObsEva Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OBSVObsEvaN/AN/AN/AN/A$7.94M$20.11M-0.1150News CoverageCEMIChembio DiagnosticsN/A$0.46flatN/A+0.0%$16.71M$48.34M-0.38337Analyst ForecastACSTAcasti Pharma2.913 of 5 stars$3.37-0.9%$10.00+196.7%+40.4%$31.68MN/A-2.9632Upcoming EarningsPositive NewsMRKRMarker Therapeutics3.5317 of 5 stars$3.52-3.8%$19.00+439.8%+16.6%$31.40M$3.31M0.0060LIANLianBio1.1771 of 5 stars$0.29flat$3.50+1,106.5%-92.8%$31.35MN/A-0.36110KALAKALA BIO4.1866 of 5 stars$6.78-3.0%$16.50+143.4%-0.1%$31.26M$3.89M-0.4930Upcoming EarningsLGVNLongeveron3.0548 of 5 stars$2.16+6.4%$8.00+270.4%-89.6%$31.02M$1.23M-0.2523Upcoming EarningsAnalyst ForecastDYAIDyadic International1.7496 of 5 stars$1.05-0.9%$6.00+471.4%-36.9%$30.95M$2.90M-3.757News CoverageELEVElevation Oncology1.9071 of 5 stars$0.52-1.9%$7.80+1,392.5%+20.4%$30.89MN/A-0.6140Upcoming EarningsALGSAligos Therapeutics4.5682 of 5 stars$9.48-0.7%$75.00+691.1%-49.8%$30.34M$15.53M-0.4690Upcoming EarningsGap UpALTSJanoneN/A$2.36-1.3%N/AN/A$30.14M$39.61M0.00170Gap Down Related Companies and Tools Related Companies Chembio Diagnostics Alternatives Acasti Pharma Alternatives Marker Therapeutics Alternatives LianBio Alternatives KALA BIO Alternatives Longeveron Alternatives Dyadic International Alternatives Elevation Oncology Alternatives Aligos Therapeutics Alternatives Janone Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OBSV) was last updated on 11/4/2024 by MarketBeat.com Staff From Our Partners2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredElection warning coming true… If you missed it, my emergency election broadcast is now available - watch it before it's too late.Porter & Company | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredA Totally New ‘Income Coin’Buckle up… Because this might shatter everything you thought you knew about "income trading." In fact, i...Crypto 101 Media | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredA new way to play the AI boom (act before November 19)There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as li...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ObsEva SA Please log in to your account or sign up in order to add this asset to your watchlist. Share ObsEva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
